AI in Clinical Trials Could Cut 10 Weeks and Save $5.6 Million, Study Finds

What the Tufts Study Actually Found

Researchers at the Tufts Center for the Study of Drug Development applied a clinical monitoring AI agent—built by Medable—to a real oncology drug development program running Phase 2 and 3 trials. The results, shared first with Axios, point to meaningful operational gains:

• ~10 weeks saved in clinical development time
• Up to $5.6 million in reduced direct operating costs per late-stage trial
• Up to $565 million in net benefits for a drug targeting 50 active tumor types

That last number scales because the efficiencies compound across indications. More targets, more trials, more savings.

According to Tufts executive director Ken Getz, this appears to be the first time predictive modeling based on actual use data has been applied to quantify the financial impact of an agentic AI solution in drug development. That’s a notable methodological step—moving from theoretical projections to grounded estimates.

Where the Time and Money Actually Come From

The gains aren’t magic. They come from three fairly unglamorous places:

• Faster patient enrollment — one of the most persistent bottlenecks in any trial
• Fewer on-site monitoring visits — reducing travel, coordination, and overhead
• Faster data locking — getting cleaner data sooner so analysis can begin earlier

Oncology trials are particularly expensive to monitor, which makes them a logical first target. The more complex the trial, the more room there is for an AI agent to absorb the grinding, repetitive work.

The “Self-Driving Car” Analogy Has Limits

Medable officials suggest AI agents could become standard features of clinical trials within three to five years—operating like self-driving cars handling the record-keeping load while humans focus on strategy.

It’s a useful analogy, but it comes with the same asterisk as actual self-driving cars: humans still need to verify the output. That verification layer could offset some of the time savings, depending on how much trust organizations are willing to extend to automated systems in a heavily regulated environment.

AI also doesn’t solve the hard, human problems in trials:

• Finding the right patients
• Getting informed consent
• Manufacturing and distributing the drug at scale

These aren’t information-processing problems. They’re logistics, ethics, and biology. No agent fixes those.

Why Oncology Is the Right Place to Start

Cancer drug trials are among the most complex and costly in the industry. They often involve multiple tumor types, large patient populations, and extensive safety monitoring. That complexity is exactly what makes them a good proving ground—the potential upside is high enough to justify the investment in new tooling.

There’s also a diversity angle worth noting. AI agents could help track the demographic composition of trial populations in real time, flagging gaps before they become a regulatory or scientific problem. That’s a quiet but genuinely useful application.

The Practical Takeaway

A 10-week reduction and $5.6 million in savings per trial won’t fix drug development. But applied across dozens of trials, across multiple indications, those numbers start to matter at the portfolio level.

The more interesting signal here isn’t the headline figure—it’s that someone finally ran the numbers on actual usage data. That moves the conversation from “AI could help” to “here’s what it did.” For anyone evaluating AI tools in regulated, high-stakes environments, that distinction is everything.